Breaking News


Open-label pilot study of alefacept for pyoderma gangrenosum


A 20-week, prospective, open-label, pilot study assessed the effects of alefacept (15 mg/week i.m.) in 4 patients with pyoderma gangrenosum, with a 12-week follow-up period. The primary efficacy endpoint was the proportion of patients achieving 'clear' or 'almost clear' on the Physician Global Assessment (PGA). Secondary endpoints comprised the percentage achieving at least a 50% decrease in lesion size (mm) and the proportion of patients achieving resolution of inflammation, with erythema and border thickness scores of 0 on a scale of 0-4. At week 20, only one patient (25%) achieved remission, two had marked and one had slight improvement. One patient had a decrease of 98% in lesion size, but the others ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list